12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CR845: Phase II started

Cara began a double-blind, placebo-controlled, U.S. Phase II trial evaluating 0.04 mg/kg IV CR845 given pre- and post-operatively in >200 female patients undergoing laparoscopic hysterectomy....

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >